Abstract:Abstract Isotretinoin is the gold-standard treatment for severe acne. Growing concerns about its association with psychiatric and sexual side-effects have led to the introduction of new monitoring requirements by the Medicines and Healthcare products Regulatory Agency. Herein we present pivotal real-world data on treatment-related psychosexual side-effects. The primary aim of this review was to evaluate mental health outcomes in terms of depressive symptoms and quality of life in patients treated with isotretinoin. Our secondary endpoint was to evaluate the effect of isotretinoin on sexual function. We conducted a retrospective cohort study of 167 consecutive patients who completed treatment with isotretinoin for acne vulgaris between 1 November 2019 and 31 October 2023. Patient Health Questionnaire-9 (PHQ-9) scores, Cardiff Acne Disability Index (CADI) scores and subjective symptom reports were collected at baseline and each follow-up until completion of treatment. We compared data on baseline characteristics, clinical and biochemical side-effects and dosing regimens for patients who met the criteria for moderate or severe depression vs. those with mild or no depressive symptoms. Mean PHQ-9 and CADI scores improved significantly following isotretinoin completion compared with baseline (P < 0.05). Twenty patients (12.0%) met the criteria for moderate or severe depression at baseline. Of these, five patients were on antidepressive therapy and two patients experienced worsening of symptoms on isotretinoin. In total 11 patients (6.5%) met the criteria for moderate or severe depression at the final follow-up; nine of these had reported no or mild depressive symptoms at baseline. Logistic regression analysis did not identify potential risk factors for psychiatric adverse effects with isotretinoin, including no correlation with the average daily or total cumulative dose. We report no cases of suicidal ideation, suicide or erectile dysfunction. A single case of low libido was noted; however, symptoms were mild and did not warrant discontinuation of treatment. The mean follow-up duration after discontinuation of treatment was 209 days. Our analysis did not identify an association of isotretinoin with new-onset depressive symptoms or sexual dysfunction above the background prevalence. The findings support an overall favourable risk profile of isotretinoin at the population level, but the possibility of rare, idiosyncratic adverse events cannot be excluded.

Evaluating the Relationship between Depression, Suicidal Thoughts, and Ulcerative Colitis in Acne Patients on Isotretinoin: A Case-Control Study

Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis

Comparison of Quality of Life, Depression, Anxiety, Suicide, Social Anxiety and Obsessive–Compulsive Symptoms Between Adolescents with Acne Receiving Isotretinoin and Antibiotics: A Prospective, Non-randomised, Open-Label Study

The effect of isotretinoin on the development of depression in patients after anti-acne treatment

Differences in Depression and Distress Between Acne Patients on Isotretinoin vs Oral Antibiotics

P075 A retrospective review of isotretinoin treatment-related psychosexual health side-effects in a tertiary dermatology clinic

Association between Isotretinoin Exposure and Inflammatory Bowel Disease: A Nationwide Case-Control Study in South Korea

PS01 (P075) A retrospective review of isotretinoin treatment-related psychosexual health side-effects in a tertiary dermatology clinic

Isotretinoin updates

Correlation between depression scores and serum NF‐ĸB/NLRP3 axis, biotinidase, and HMGB1 after treatment with isotretinoin in patients with acne vulgaris

The Role of Serum Lipids in Predicting Suicidal Ideation in Isotretinoin Therapy for Acne

A novel predictive method for risk stratification in acne patients receiving isotretinoin: an analysis of laboratory abnormalities and changes in inflammatory parameters

The occurrence of mental health symptoms in isotretinoin‐treated adolescents

Psychiatric disorders, acne and systemic retinoids: comparison of risks

Investigating metabolic syndrome markers and body mass index changes in patients with acne vulgaris treated with isotretinoin: A prospective study

Risk and timing of isotretinoin‐related laboratory disturbances: a population‐based study

The use of isotretinoin for acne – an update on optimal dosing, surveillance, and adverse effects

Evaluation of isotretinoin effects on depression, sleep apnea and sleep quality

Laboratory investigations of liver function and lipid profiles tests before and after oral isotretinoin treatment among Acne valgaris clients at Ibri Polyclinic: A retrospective study

Isotretinoin for acne and rosacea

Investigation of systemic immune-inflammation index and systemic inflammation response index as an indicator of the anti-inflammatuary effect of isotretinoin in patients with acne vulgaris